[Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations].
This study tests the possibility to avoid the use of phenformin in 40 type 2 (non insulin dependent) diabetic patients treated with the commercial sulphonylurea-phenformin combinations. In diabetic patients treated with sulphonylureas and phenformin at low dosage (glibenclamide 5 mg and phenformin 50 mg) it was possible to maintain good glycometabolic control using only the sulphonylurea gliclazide (160 mg/die). The diabetic patients on treatment with sulphonylureas and phenformin at higher dosage (glibenclamide 7.5 mg and phenformin 75 mg) may further improve their metabolic control when transferred to a gliclazide-benfluorex combination 160 mg and 300 mg/die, respectively. These results suggest the possibility of withdrawing or replacing phenformin in the therapy of type 2 diabetic patients without modifying their glycometabolic control.
Di Cianni
G
G
Istituto di Clinica Medica II, Università degli Studi di Pisa.
Benzi
L
L
Ciccarone
A M
AM
Cecchetti
P
P
Giannarelli
R
R
Penno
G
G
Navalesi
R
R
D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005907:Gliclazide / Q000008:administration & dosage*; D005905:Glyburide / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000008:administration & dosage*; D013997:Time Factors
D001786:Blood Glucose; D005277:Fenfluramine; C001584:benfluorex; D010629:Phenformin; D005907:Gliclazide; D005905:Glyburide
Efficacia della terapia con sulfaniluree e sulfaniluree-benfluorex in pazienti con diabete di tipo II trattati con associazioni sulfaniluree-biguanidi del commercio.